With its patent representing both a validation of its research and model and a potential new revenue stream), 23andMe now wants to double down on patient and community-driven research. And to better follow their first patent than with their first acquisition, on Tuesday, the company officially announced that it is scooping up the four-year-old CureTogether, a similarly-focused startup that aims to give people the tools they need to create their own research studies, learn about their health, and connect with experts and others who suffer from similar conditions.
The deal makes a lot of sense from both sides. The two startups have complementary platforms, and there’s no doubt that 23andMe sees those four million phenotypic data points as a valuable addition to its database, using them to inform their research and no doubt develop further vulnerability assessments for diseases beyond Parkinson’s. CureTogether, on the other hand, which has been plodding along at a consistent pace, building a respected support and education community, could have continued on course.
Founded in 2010, the industry website, Crowdsourcing.org, is a neutral organization dedicated solely
to crowdsourcing and crowdfunding. As one of the most influential and credible authorities in the crowdsourcing space,
Crowdsourcing.org is recognized worldwide for its intellectual capital, crowdsourcing and crowdfunding
practice expertise and unbiased thought leadership.